Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRYM03)

Drug Name
HMS5552 Drug Info
Synonyms
Dorzagliatin; UNII-X59W6980E8; X59W6980E8; 1191995-00-2; Sinogliatin; RO5305552; Dorzagliatin [INN]; Dorzagliatin [USAN:INN]; SCHEMBL1079619; HMUMWSORCUWQJO-QAPCUYQASA-N; HMS-5552; AKOS030527745; RO-5305552; (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5; (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R; (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,3-dihydroxy-propyl)-1H-pyrazol-3-yl]-amide; (2S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Phase 1 [1]
Cross-matching ID
PubChem CID
57920094
CAS Number
CAS 1191995-00-2
TTD Drug ID
DMRYM03

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glucokinase (GCK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY-2599506 DMMI0RH Diabetic complication 5A2Y Phase 2 [2]
AMG 151 DMGOFL3 Type-2 diabetes 5A11 Phase 2 [2]
PF-04991532 DM94NBE Diabetic complication 5A2Y Phase 2 [3]
GK1-399 DMLFSMX Diabetic complication 5A2Y Phase 2 [4]
LY-2608204 DM4EF9Y Type-2 diabetes 5A11 Phase 2 [5]
PF-04937319 DMQMF4O Type-2 diabetes 5A11 Phase 2 [6]
AZD1656 DMUE90I Diabetic complication 5A2Y Phase 2 [7]
TTP399 DMBKQSZ Type 2 diabetes 5A11 Phase 2 [8]
BMS-820132 DMCX0H7 Type-2 diabetes 5A11 Phase 1 [9]
DS-7309 DM7C4U9 Diabetic complication 5A2Y Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucokinase (GCK) TTDLNGZ HXK4_HUMAN Activator [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009
3 The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139.
4 Clinical pipeline report, company report or official report of vTv Therapeutics, NCT02405260.
5 Clinical pipeline report, company report or official report of Eli Lilly.
6 Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.
7 Clinical pipeline report, company report or official report of AstraZeneca (2009).
8 Clinical pipeline report, company report or official report of vTv Therapeutics.
9 Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities. Toxicol Pathol. 2015 Aug;43(6):825-37.
10 Glucokinase alternative. SciBX 6(45); doi:10.1038/scibx.2013.1279. Nov. 21 2013